Statin use after cancer diagnosis and survival among patients with cancer
The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Abstract
Purpose The association between statin use and cancer survival has been investigated in previous studies with conflicting findings. This study aimed to assess the association between statin use following cancer diagnosis and survival in six common cancers using the Surveillance, Epidemiology, and End Results (SEER)-Medicare database. Methods Individuals aged ≥ 66 years diagnosed with prostate cancer, colorectal cancer, lung cancer, bladder cancer, pancreatic cancer, or non-Hodgkin lymphoma (NHL) from 2008 through 2017 were identified. Statin use was defined as two or more statin prescription fills after cancer diagnosis. Time-dependent Cox proportional hazard regression models were used to estimate the association between statin use and cancer-specific mortality for each cancer. Results This study included 34,618 patients with prostate cancer (median follow-up 4.0 years), 20,579 with colorectal cancer (2.9 years), 20,133 with lung cancer (1.7 years), 6,163 with bladder cancer (2.1 years), 4,538 with pancreatic cancer (0.8 years), and 3,270 with NHL (2.9 years). Statin use post-diagnosis was associated with a reduced risk of cancer-specific mortality in lung cancer (hazard ratio [HR], 0.81; 95% confidence interval [CI], 0.74-0.88) and pancreatic cancer (HR, 0.72; 95% CI, 0.59-0.87). The association was not statistically significant for prostate cancer, colorectal cancer, bladder cancer, or NHL. A dose-response relationship by duration of statin use was observed in lung cancer…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Evidence from large population-based cohorts demonstrates mixed results regarding the relationship between statin use and PDAC incidence or survival outcome, with some cohorts showing variable protective effects and others showing a survival benefit of statin exposure, as shown in Table 1”
From The antitumoral effect of statins in pancreatic ductal adenocarcinoma: a scoping review (2026) · cites this paper as Guo et al., 2025
In the citing paper
“Guo et al. reported a benefit on OS for the PDAC patients treated with statins after diagnosis compared with the PDAC patients never treated with statins.”
From The antitumoral effect of statins in pancreatic ductal adenocarcinoma: a scoping review (2026) · cites this paper as Guo et al., 2025
In the citing paper
“with higher benefits on OS in the 1–2 years category compared to <1 category, and respectively 2–3 years category compared to 1–2 years category, with a ptrend value of 0.04 (Guo et al., 2025).”
From The antitumoral effect of statins in pancreatic ductal adenocarcinoma: a scoping review (2026) · cites this paper as Guo et al., 2025
Citations
Cites
Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2022) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21708 · Cited by 17,196
mice: Multivariate Imputation by Chained Equations in R
Buuren, S. V., & Groothuis-Oudshoorn, K. (2011) · Journal of Statistical Software · doi:10.18637/jss.v045.i03 · Cited by 13,870
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000625 · Cited by 6,185
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.002 · Cited by 1,751
Levesque, L. E., Hanley, J. A., Kezouh, A., & Suissa, S. (2010) · BMJ · doi:10.1136/bmj.b5087 · Cited by 1,182 · cited 1×
“…selection bias due to the inclusion of prevalent users (individuals with pre-diagnosis statin exposure) and immortal time bias due to inappropriately classifying unexposed survival time before statin initiation as exposed, which could lead to overestimation of the benefits of statins [17–19].”
Statin use and reduced cancer-related mortality
Nielsen, S. F., Nordestgaard, B. G., & Bojesen, S. E. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1201735 · Cited by 1,030 · cited 1×
“All of the previous cohort studies on pancreatic cancer either only evaluated overall survival [34, 39–44] or only focused on pre-diagnosis use [45].”
Statins Have Biphasic Effects on Angiogenesis
Weis, M., Heeschen, C., Glassford, A. J., & Cooke, J. P. (2002) · Circulation · doi:10.1161/hc0602.103393 · Cited by 680 · cited 1×
“Statins have been shown to be pro-angiogenic at low therapeutic concentrations but anti-angiogenic at high concentrations in vitro [36].”
Use of Statins and the Risk of Death in Patients With Prostate Cancer
Yu, O., Eberg, M., Benayoun, S., Aprikian, A., Batist, G., Suissa, S., & Azoulay, L. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.4757 · Cited by 659
Shrank, W. H., Patrick, A. R., & Alan Brookhart, M. (2011) · Journal of General Internal Medicine · doi:10.1007/s11606-010-1609-1 · Cited by 630 · cited 1×
“This suggests that any potential protective effect of statins may be exhibited only with long-term use in prostate cancer, but the influence of healthy adherer bias cannot be ruled out [35].”
Salami, J. A., Warraich, H., Valero-Elizondo, J., Spatz, E. S., Desai, N. R., Rana, J. S., Virani, S. S., Blankstein, R., Khera, A., Blaha, M. J., et al. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2016.4700 · Cited by 370
Research works printed but not linked: 3
- Warren JL et al (2002) Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 40(8):3–18
- Enewold L et al (2020) Updated overview of the SEER-medicare data: enhanced content and applications. J Natl Cancer Inst Monogr 2020(55):3–13
- Rubin DB (2009) Multiple Imputation for Nonresponse in Surveys. 2009: Wiley
Cited by
Yang, J., Lin, J., Guo, H., Wu, W., Wang, J., Mao, J., Fan, W., Yang, L., Wang, Y., & Yan, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1638677 · Cited by 6
Self-citationArtner, A., Diler, I., Hankó, B., Sebők, S., & Zelkó, R. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14155436 · Cited by 1
“Third, the temporal relationship between statin initiation and cancer diagnosis remains poorly characterized across studies, potentially affecting the magnitude of observed benefits [56,58].”
Yuan, S., Li, B., Jiang, Y., Shen, L., Fu, Z., & Liu, L. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1792449 · Cited by 1
The antitumoral effect of statins in pancreatic ductal adenocarcinoma: a scoping review
Pîntea, A.-I., Croitoru, A. E., Dinu-Pîrvu, C. E., & Dima, S. O. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1815366
“…on survival was analyzed on statin use duration categories: < 1 year, 1–2 years, 2–3 years, > 3 years, with higher benefits on OS in the 1–2 years category compared to 1 category, and respectively 2–3 years category compared to 1–2 years category, with a p trend value of 0.04 (Guo et al., 2025).”
InfluentialPotassium channels in cancer: from hallmarks to therapeutic targeting
Zhang, Y.-L., Shi, R.-J., & Liang, X. (2026) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-026-01228-5
Metadata
- Authors
- Guo, H., Malone, K. E., Heckbert, S. R., & Li, C. I.
- Affiliations
- University of Washington (US)
- Corresponding author
- Li, Christopher I.
- Venue
- Cancer Causes & Control
- Published
- 2024-12-25
- Volume
- 36
- Issue
- 4
- Pages
- 443-455
- ISSN
- 0957-5243 (ISSN-L)
- 1573-7225
- OpenAlex
- W4405746232
- Cited by
- 4
- References
- 63
- Citations by year
- 2026: 2 · 2025: 2
- FWCI
- 0.80
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Cancer Causes & Control (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (T32CA09168)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Stress, Anesthesia, and Immune Response
- Keywords
- statins, cancer-specific mortality, cancer survival, lung cancer, pancreatic cancer, prostate cancer, colorectal cancer, bladder cancer, non-Hodgkin lymphoma, statin therapy, dose-response relationship, SEER-Medicare
- MeSH terms
- Aged, Aged, 80 and over, Urinary Bladder Neoplasms, Female, Follow-Up Studies, Humans, Lung Neoplasms, Male, Neoplasms, United States, Survival Rate, SEER Program, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Statin use after cancer diagnosis and survival among patients with cancer. https://app.cochat.ai/papers/10.1007/s10552-024-01939-4
- The paper
- Guo, H., Malone, K. E., Heckbert, S. R., & Li, C. I. (2025). Statin use after cancer diagnosis and survival among patients with cancer. Cancer Causes & Control. https://doi.org/10.1007/s10552-024-01939-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.